Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 16, Issue 10, pp. 2760-2768
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 6, 2010
- Revision received March 16, 2010
- Accepted March 28, 2010
- Published first May 11, 2010.
Article Versions
- Previous version (May 11, 2010 - 09:43).
- You are viewing the most recent version of this article.
Copyright & Usage
©2010 American Association for Cancer Research.
Author Information
- Joseph M. Tuscano1,2,
- Shiloh M. Martin1,
- Yunpeng Ma1,
- William Zamboni3,4,5,6, and
- Robert T. O'Donnell1,2
- Authors' Affiliations: 1Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis, 2Northern California Veteran's Administration Healthcare System, 3Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, 4Molecular Therapeutics Program, UNC Lineberger Comprehensive Cancer Center, 5UNC Institute for Pharmacogenomics and Individualized Therapy, 6Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina, Chapel Hill, North Carolina
- Corresponding Author:
Joseph Tuscano, UC Davis Cancer Center, Division of Hematology and Oncology, 4501 X Street, Suite 3016, Sacramento, CA. 95817. Phone: 916-734-3771; Fax: 916-734-2361; E-mail: joseph.tuscano{at}ucdmc.ucdavis.edu.
May 2010
Volume 16, Issue 10
Volume 16, Issue 10
Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model
Jump to section
Advertisement